Puma Biotechnology (PBYI)
(Delayed Data from NSDQ)
$3.07 USD
-0.04 (-1.29%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.06 -0.01 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PBYI 3.07 -0.04(-1.29%)
Will PBYI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PBYI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PBYI
Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
PBYI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors
Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease
AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer
Other News for PBYI
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results | ...
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | PBYI Stock News
Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment
Puma Biotechnology Updates Bylaws for Compliance
Puma Biotechnology Holds Annual Stockholders Meeting 2025